Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
GRAIL, LLC has partnered with the U.S. Department of Veterans Affairs to offer the Galleri multi-cancer early detection test to 10,000 veterans across 10 sites over three years, starting with the VA Pittsburgh Healthcare System. This collaboration is part of the REFLECTION study, which aims to evaluate the test's performance alongside traditional screenings. The Galleri test can identify signals from over 50 cancer types, which is crucial for earlier and potentially curative treatment.
Illumina has announced the CE-marking of its TruSight™ Oncology Comprehensive (EU) test as the first companion diagnostic for Bayer's VITRAKVI® (larotrectinib) targeting NTRK fusion cancer patients. This comprehensive genomic profiling test can identify multiple tumor gene fusions across various solid tumor types, enhancing patient access to precision therapies. The CDx claim stems from extensive clinical validation involving data from three pivotal trials that support the efficacy of larotrectinib in eligible patients. Illumina plans to expand its CDx offerings through partnerships in oncology.
Illumina (NASDAQ: ILMN) has partnered with Allegheny Health Network (AHN) to evaluate in-house comprehensive genomic profiling (CGP) to enhance cancer care. The collaboration will analyze the effectiveness of blood-based testing compared to traditional tissue samples in identifying genetic variations that affect treatment choices. The study will involve around 1,000 samples across 24 oncology clinics. The project aims to improve patient outcomes by facilitating personalized therapy, with a focus on less invasive procedures. The initiative commenced in 2022 and is expected to last one year.
GRAIL, LLC, in collaboration with Intermountain Healthcare, is introducing the Galleri® multi-cancer early detection blood test, aimed at enhancing cancer care through early detection. Starting this month, eligible patients over 50 or with heightened cancer risk factors will have access to the test. Galleri can detect signals from over 50 cancer types, many of which lack standard screenings, boasting a low false positive rate of under 1%. This partnership aims to advance screening capabilities, reflecting a commitment to proactive cancer care.
A comprehensive analysis of 2 million Medicare beneficiaries reveals that the cost of cancer rises significantly with later diagnosis. Conducted by PHAR and GRAIL, the study indicates that late-stage cancer diagnosis can be up to seven times costlier and that these elevated costs persist for at least five years. Annual cancer care expenses total $1 trillion, highlighting the economic impact of late detection. This research provides crucial insights for healthcare professionals and emphasizes the importance of early diagnosis to mitigate costs.
Illumina reported Q1 2022 revenue of $1.22 billion, a 12% increase year-over-year. However, diluted EPS fell to $0.55 from $1.00 in Q1 2021. Despite these results, the company reaffirms its 2022 revenue growth guidance of 14-16% and expects diluted EPS of $2.33 to $2.53. GRAIL, acquired in 2021, showed promising partnerships but reported an operating loss of $172 million. Illumina continues to advance in oncology and genetic testing, with cash reserves at $1.4 billion.
Illumina (NASDAQ: ILMN) and Deerfield Management have announced a five-year partnership aimed at revolutionizing drug discovery through a genetics-led approach. This collaboration seeks to enhance the identification of therapeutic targets and expedite the development of novel therapies for unmet medical needs. Leveraging genomic tools and artificial intelligence, the partnership aims to reduce the high costs and long timelines associated with drug development, fostering more efficient paths to market for potentially life-saving treatments.
Illumina, Inc. (NASDAQ: ILMN) will participate in the BofA Securities 2022 Healthcare Conference on May 12, 2022. The fireside chat will take place at 12:00pm PT (3:00pm ET). Investors can access the live webcast on Illumina's website in the Investor Info section. A replay will be available for 30 days post-event. Illumina focuses on DNA sequencing and array-based technologies, enhancing human health through genomic insights across several sectors including oncology and agriculture.
Illumina (NASDAQ: ILMN) announced a collaboration with Hannover Medical School to enhance genetic disorder diagnosis using whole-genome sequencing (WGS) for critically ill children. The study will involve at least 100 patients and aims to demonstrate the efficacy of rapid WGS in providing timely diagnoses and treatment. This initiative intends to reshape eligibility criteria for WGS in German healthcare, amid growing global evidence of its clinical value. Illumina will supply necessary reagents, highlighting the significant impact of WGS in pediatric precision medicine.
The PGA TOUR Champions has partnered with GRAIL to host the inaugural Galleri Classic from March 20-26, 2023, at the historic Mission Hills Country Club in Rancho Mirage, California. The tournament will feature 78 professionals competing for a total purse of $2.2 million. This marks the first PGA TOUR Champions event in Coachella Valley since 1993 and aims to raise awareness for multi-cancer early detection. GRAIL, a subsidiary of Illumina (ILMN), focuses on early cancer detection technologies.